Ascentage Pharma Group clinical trials we track

Check company identity source

Phase 3 7 trials

Phase 2 3 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters
Study of Olverembatinib (HQP1351) in Patients With CML-CP

NCT06423911 · Ascentage Pharma Group Inc.

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: MMR rate Part A Measure: MMR rate Part B. After: Measure: 24-Week MMR Rate (Part A) Measure: 24-Week MMR Rate (Part B).

Planned enrollment increased by 48 participants

Before: 285 participants (planned). After: 333 participants (planned).

Primary completion date changed

Before: Dec 2025. After: 30 Jun 2027.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Minimal residual disease negativity rate. After: Measure: Minimal Residual Disease Negative CR Rate.

Primary completion date changed

Before: 31 Dec 2024. After: 31 Dec 2027.

Check registry source